In the drug-eluting stent industry, large companies overturned the innovation paradigm, developing revolutionary new products on their own and leaving small companies--usually the medical device industry's source of innovation--on the sidelines. In 2008, four large companies held the lion's share of a $4.2 billion worldwide market for drug-eluting stents, with, according to recent estimates, Boston Scientific Corp. holding a 49% share of the US market, newest entrant Abbott Laboratories Inc. coming up fast with a 27% share, and Johnson & Johnson and Medtronic PLC each taking 12% portions of the pie. (For a comprehensive discussion of the state of the drug-eluting stent industry, see the recent article, "The Future of Drug-Eluting Stents, Part I: Novel Next-Generation Designs," Medtech Insight, November 2009 Also see "The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs" - Medtech Insight, 1 November, 2009..)
Start-up companies have tried to take back their rightful place as innovators over the years: early on, by trying to specialize in things large medical device companies weren't good at,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?